Coronavirus vaccine prospects boost Moderna premarket, up 6% 
 Moderna (NASDAQ:MRNA) perks up   premarket on light volume on the heels of the news of a coronavirus outbreak in China (SARS 2.0, so to speak). Investors perceive that it may be a player in developing a vaccine considering that it is developing the same for CMV, RSV, hMPV/PIV3, Zika and influenza H7N9.

Yesterday's top mover, NanoViricides (NYSEMKT:NNVC), is down   premarket in reaction to its stock offering while Novavax (NASDAQ:NVAX) is down  . On the plus side, Aethlon Medical (NASDAQ:AEMD) is up  , Inovio Pharmaceuticals (NASDAQ:INO) up  , BioCryst Pharmaceuticals (NASDAQ:BCRX) up   and Nabriva Therapeutics (NASDAQ:NBRV) up  .